| | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-09-03 | 24.60 | -1.40% | 2309.63万 | 5.97% | 413.61万 | 1.07% | -2723.24万 | -7.03% | | 2025-09-02 | 24.95 | -1.03% | 4783.89万 | 9.05% | -669.18万 | -1.27% | -4114.70万 | -7.79% | | 2025-09-01 | 25.21 | 4.65% | 7537.79万 | 11.23% | 3461.42万 | 5.16% | -1.10亿 | -16.39% | | 2025-08-29 | 24.09 | -4.25% | -4484.24万 | -8.07% | 387.69万 | 0.70% | 4096.54万 | 7.37% | | 2025-08-28 | 25.16 | -1.64% | -3 ...

Core Viewpoint - As of September 1, 2025, Meihao Medical (301363) closed at 25.21 yuan, marking a 4.65% increase, with significant trading activity and mixed capital flows [1][2]. Group 1: Stock Performance - On September 1, 2025, the stock price increased by 4.65% with a trading volume of 271,900 hands and a total transaction amount of 671 million yuan [1]. - The stock experienced a net inflow of 75.38 million yuan from main funds, accounting for 11.23% of the total transaction amount, while retail investors saw a net outflow of 110 million yuan, representing 16.39% of the total [1][2]. Group 2: Financing and Margin Trading - On September 1, 2025, the financing buy amounted to 81.20 million yuan, with a net financing buy of 715,000 yuan, while the margin trading balance stood at 1.59 billion yuan [2][3]. - The stock's margin trading data indicated a total of 3.72 million shares in margin trading, with a margin balance of 937,300 yuan [3]. Group 3: Financial Metrics and Industry Comparison - Meihao Medical reported a total market value of 14.34 billion yuan, with a net profit of 114 million yuan, reflecting a year-on-year decline of 32.44% [5]. - The company's gross profit margin was 37.52%, significantly lower than the industry average of 51.85%, while its net profit margin was 15.6%, higher than the industry average of 10.39% [5]. - The company’s return on equity (ROE) was 3.23%, outperforming the industry average of 1.8% [5]. Group 4: Institutional Ratings - In the last 90 days, 16 institutions rated the stock, with 14 buy ratings and 2 hold ratings, and the average target price set at 26.48 yuan [6].

Group 1 - The core viewpoint of the news is that Meihao Medical experienced a decline in stock price, dropping by 5.01% to 23.90 CNY per share, with a trading volume of 349 million CNY and a turnover rate of 9.16%, resulting in a total market capitalization of 13.596 billion CNY [1] - Meihao Medical, established on July 15, 2010, and listed on October 12, 2022, is located in Longgang District, Shenzhen, Guangdong Province, and specializes in the design, development, manufacturing, and sales of precision components and products for medical devices [1] - The revenue composition of Meihao Medical includes: 59.48% from home respiratory machine components, 14.61% from home and consumer electronics components, 10.33% from other medical product components, 8.16% from cochlear implant components, 5.63% from precision molds and automation equipment, 1.09% from other categories, and 0.70% from proprietary products [1] Group 2 - From the perspective of Meihao Medical's top ten circulating shareholders, Huabao Fund holds a position in the company, with its Huabao CSI Medical ETF (512170) increasing its holdings by 1.6179 million shares in the second quarter, totaling 5.694 million shares, which accounts for 3.64% of the circulating shares [2] - The Huabao CSI Medical ETF (512170), established on May 20, 2019, has a latest scale of 26.147 billion CNY, with a year-to-date return of 16.62% and a one-year return of 41.01% [2] - The fund manager of Huabao CSI Medical ETF (512170) is Hu Jie, who has a cumulative tenure of 12 years and 321 days, managing total assets of 84.336 billion CNY, with the best fund return during his tenure being 143.28% and the worst being -98.01% [2]

证券之星消息，截至2025年8月28日收盘，美好医疗(301363)报收于25.16元，下跌1.64%，换手率 15.39%，成交量24.05万手，成交额6.03亿元。 8月28日的资金流向数据方面，主力资金净流出3102.85万元，占总成交额5.15%，游资资金净流入 120.23万元，占总成交额0.2%，散户资金净流入2982.62万元，占总成交额4.95%。 近5日资金流向一览见下表： | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-08-28 | 25.16 -1.64% | -3102.85万 | -5.15% | 120.23万 | 0.20% | 2982.62万 | - 4.95% | | 2025-08-27 | 25.58 4.45% | 1503.76万 | 1.23% | -4030.37万 | -3.30% | 2526.60万 | 2.07% | | 2025-08-26 | 24.49 -8.00% ...

Core Viewpoint - The company has taken on all production processes for cochlear implant products, excluding PCBA and chip manufacturing, indicating a strong capability in precision manufacturing and design for brain-machine interface products [1] Group 1 - The company has the ability to expand its technical reserves to develop and manufacture various types of brain-machine interface products due to the technological commonalities between cochlear implants and other brain-machine interface products [1] - The company is currently engaging with several domestic and international clients for collaboration and research and development efforts [1]

Core Viewpoint - The company is actively monitoring the development trends of brain-machine interface technologies and is expanding its customer base in this area, particularly in relation to cochlear implants as a successful application of such technologies [1] Group 1: Company Strategy and Operations - The company is a leading global player in the cochlear implant field and serves as a strategic partner and core supplier for related technologies [1] - The company has accumulated extensive practical experience in product design, technology research and development, material application, precision manufacturing, mass production transformation, and quality management systems for Class III implantable medical devices [1] - The company has undertaken all production processes for cochlear implant products, except for PCBA and chip manufacturing [1] Group 2: Technology and Market Development - The company possesses the capability to extend its technological reserves to the research, design, and precision manufacturing of various brain-machine interface products due to the technical commonalities with cochlear implants and stringent quality control standards [1] - The company has initiated discussions and research collaborations with several domestic and international clients regarding brain-machine interface technologies, although specific details are confidential [1]

（文章来源：证券日报） 证券日报网讯美好医疗8月27日在互动平台回答投资者提问时表示，公司以自主研发为主，并结合前沿 技术发展方向和产品定制化要求与客户及科研机构开展研发合作。公司研发中心协同战略市场等部门组 建专项项目团队，围绕细分领域的技术演化轨迹与产品迭代路径开展前瞻性技术预研工作；同时，通过 动态追踪客户产品升级规划与新品开发进程，提前构建技术应用储备库与产品解决方案矩阵。前置性研 发工作模式有效强化了公司对行业技术演变的敏捷响应能力，显著压缩了技术转化周期，并通过引导新 技术和新工艺在客户产品开发方面的有效应用，持续增强细分领域的核心技术竞争优势。 ...

Investment Rating - The investment rating for the company is "Accumulate" [7] Core Views - The company is a leading player in home respiratory devices and cochlear implant components, with expectations for a performance rebound in the second half of 2025 due to the easing of short-term tariff disruptions and the acceleration of new business developments in blood glucose monitoring, brain-computer interfaces, and robotics [1][5] Summary by Sections Business Performance - In the first half of 2025, the company's overseas revenue accounted for approximately 87%, with a decline in revenue from home respiratory device components by 2.8% and cochlear implant revenue by 7.5% due to tariff disruptions. The company's net profit attributable to shareholders was 114 million yuan, a year-on-year decrease of 32.44% [2] New Product Development - The company has seen a 54.4% year-on-year increase in revenue from other medical product components, reaching 76 million yuan in the first half of 2025. The insulin pen and CGM components are expected to contribute to the next growth point, with the insulin pen project achieving large-scale production [3] Technological Expansion - The company is expanding its technology platform into brain-computer interfaces and robotics, leveraging its expertise in electrode precision processing from cochlear implants. This expansion is expected to open long-term growth opportunities [4] Financial Forecast and Valuation - Revenue projections for 2025-2027 are 1.895 billion, 2.375 billion, and 2.915 billion yuan, with year-on-year growth rates of 18.85%, 25.34%, and 22.74%, respectively. Net profit attributable to shareholders is forecasted to be 424 million, 543 million, and 653 million yuan for the same period, with corresponding growth rates of 16.64%, 27.97%, and 20.26% [5][11]

New Stock Offerings - Shenke Co., Ltd. (002633) has an offer period from July 29, 2025, to August 27, 2025[1] - Fushun Special Steel (600399) has an offer period from August 12, 2025, to September 10, 2025[1] - ST Gaohong (000851) has an announcement on August 26, 2025[1] Market Volatility - Great Wall Military Industry (601606) reported severe abnormal fluctuations on August 14, 2025[1] - Dongxin Co., Ltd. (688110) had an announcement on August 16, 2025, regarding market conditions[1] - Changfei Optical Fiber (601869) has an announcement dated August 27, 2025, related to market performance[1] Company Announcements - ST Dehao (002005) has an announcement on August 27, 2025, regarding its market status[1] - China Satellite (600118) announced updates on August 27, 2025[1] - ST Yizhong (603389) has an announcement dated August 26, 2025, regarding its market activities[1]

Group 1 - The company, Meihua Medical, stated on August 27 that as of August 20, 2025, the total number of shareholders is 17,239 [2]